Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC)

References

• Hanno P, Dmochowski R. Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn. 2009;28:274–286.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Weng SF, Hsu YW, et al. Increased risks of healthcare-seeking behaviors of anxiety, depression and insomnia among patients with bladder pain syndrome/interstitial cystitis: a nationwide population-based study. Int Urol Nephrol. 2015;47:275–281.
   PubMed Web of Science ®Google Scholar
• Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987. J Urol. 1988;140:203–206.
   PubMed Web of Science ®Google Scholar
• Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186:540–544.
   PubMed Web of Science ®Google Scholar
• Suskind AM, Betty SH, Ewing BA, et al. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology Male Study. J Urol. 2013;189:141–145.
   PubMed Web of Science ®Google Scholar
• Rosenberg MT, Hazzard M. Prevalence of interstitial cystitis symptoms in women: a population based study in the primary care office. J Urol. 2005;174:2231–2234.
   PubMed Web of Science ®Google Scholar
• Moutzouris DA, Falagas ME. Interstitial cystitis: an unsolved enigma. Clin J Am Soc Nephrol. 2009;4:1844–1857.
   PubMed Web of Science ®Google Scholar
• Hurst RE. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol. 1994;12:3–10.
   PubMed Web of Science ®Google Scholar
• Parsons CL, Greene RA, Chung M, et al. Abnormal urinary potassium metabolism in patients with interstitial cystitis. J Urol. 2005;173:1182–1185.
   PubMed Web of Science ®Google Scholar
• Ustinova EE, Fraser MO, Pezzone MA. Cross-talk and sensitization of bladder afferent nerves. Neurourol Urodyn. 2010;29:77–81.
   PubMed Web of Science ®Google Scholar
• Engeler D, Baranowski AP, Borovicka J, et al. EAU guidelines on chronic pelvic pain. 2015. Available from: http://uroweb.org/wp-content/uploads/25-Chronic-Pelvic-Pain_LR_full.pdf
   Google Scholar
• Hsu CC, Chuang YC, Chancellor MB. Intravesical drug delivery for dysfunctional bladder. Int J Urol. 2013;20:552–562.
   PubMed Web of Science ®Google Scholar
• Apodaca G. The uroepithelium: not just a passive barrier. Traffic. 2004;5:117–128.
   PubMed Web of Science ®Google Scholar
• Dellis A, Papatsoris AG. Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injections. Expert Opin Investig Drugs. 2014;23(6):751–757.
   PubMed Web of Science ®Google Scholar
• Parsons CL, Housley T, Schmidt JD, et al. Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994;73:504–507.
   PubMedGoogle Scholar
• Kuo HC. Urodynamic results of intravesical heparin therapy for women with frequency urgency syndrome and interstitial cystitis. J Formosan Med Assoc. 2001;100:309–314.
   PubMed Web of Science ®Google Scholar
• Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology. 2005;65:45–48.
   PubMed Web of Science ®Google Scholar
• Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol. 1991;145:732–735.
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Selzer MG, Unwala DJ, et al. Uronate peaks and urinary hyaluronic acid levels correlate with interstitial cystitis severity. J Urol. 2006;176:1001–1007.
   PubMed Web of Science ®Google Scholar
• Morales A, Emerson L, Nickel JC, et al. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol. 1996;156:45–48.
   PubMed Web of Science ®Google Scholar
• Shao Y, Shen ZJ, Rui WB, et al. Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis. Urology. 2010;75:547–550.
   PubMed Web of Science ®Google Scholar
• Lv YS, Zhou HL, Mao HP, et al. Intravesical hyaluronic acid and alkalinized lidocaine for the treatment of severe painful bladder syndrome/interstitial cystitis. Int Urogynecol J. 2012;23:1715–1720.
   PubMed Web of Science ®Google Scholar
• Hurst RE, Roy JB, Min KW, et al. A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology. 1996;48:817–821.
   PubMed Web of Science ®Google Scholar
• Hauser PJ, Buethe DA, Califano J, et al. Restoring barrier function to acid damaged bladder by intravesical chondroitin sulfate. J Urol. 2009;182:2477–2482.
   PubMed Web of Science ®Google Scholar
• Steinhoff G, Ittah B, Rowan S. The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J Urol. 2002;9:1454–1458.
   PubMedGoogle Scholar
• Gülpınar O, Kayış A, Süer E, et al. Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphatetherapy for patients with bladder pain syndrome/interstitital cystitis. Can Urol Assoc J. 2014;8:E610–E614.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Hanno P, Kumar K, et al. Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology. 2012;79:1220–1224.
   PubMed Web of Science ®Google Scholar
• Sant GR. Intravesical 50% dimethyl sulfoxide (Rimso-50) in treatment of interstitial cystitis. Urology. 1987;29:17–21.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Dapergolas G, Neerunjun ED. Penetration of target areas in the rat by liposome-associated agents administered parenterally and intragastrically. Biochem Soc Trans. 1976;4:256–259.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995;13:527–537.
   PubMed Web of Science ®Google Scholar
• Fraser MO, Chuang YC, Tyagi P, et al. Intravesical liposome administration – a novel treatment for hyperactive bladder in the rat. Urology. 2003;61:656–663.
   PubMed Web of Science ®Google Scholar
• Lee WC, Chiang PH, Tain YL, et al. Sensory dysfunction of bladder mucosa and bladder oversensitivity in a rat model of metabolic syndrome. PLoS One. 2012;7:e45578.
   PubMed Web of Science ®Google Scholar
• Olivera A, Rivera J. Sphingolipids and the balancing of immune cell function: lessons from the mast cell. J Immunol. 2005;174:1153–1158.
   PubMed Web of Science ®Google Scholar
• Tyagi P, Kashyap MP, Kawamorita N, et al. Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome. ISRN Pharmacol. 2014;15:601653.
   Google Scholar
• Chuang YC, Lee WC, Lee WC, et al. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009;182:1393–1400.
   PubMed Web of Science ®Google Scholar
• Lee WC, Chuang YC, Lee WC, et al. Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome. Kaohsiung J Med Sci. 2011;27:437–440.
   PubMed Web of Science ®Google Scholar
• Peters KM, Hasenau D, Killinger KA, et al. Liposomal bladder instillations for IC/BPS: an open-label clinical evaluation. Int Urol Nephrol. 2014;46:2291–2295.
   PubMed Web of Science ®Google Scholar
• Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol. 2004;171:2128–2137.
   PubMed Web of Science ®Google Scholar
• Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(Suppl 5):21–29.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Kuo HC, Chancellor MB. Botulinum toxin for the lower urinary tract. BJU Int. 2010;105:1046–1058.
   PubMed Web of Science ®Google Scholar
• Hanna-Mitchell AT, Wolf-Johnston AS, Barrick SR, et al. Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. Neurourol Urodyn. 2015;34:79–84.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol. 2004;172:1529–1532.
   PubMed Web of Science ®Google Scholar
• Apostolicism A, Poppet R, Yangon Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of Botulinum toxin for human detrusor overactivity. J Urol. 2005;174:977–982.
   PubMed Web of Science ®Google Scholar
• Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–133.
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol. 2006;175:2341–2344.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide induced cystitis in rats. Eur Urol. 2009;56:159–166.
   PubMed Web of Science ®Google Scholar
• Jiang YH, Liao CH, Kuo HC. Current and potential urological applications of botulinum toxin A. Nat Rev Urol. 2015;12:519–533.
   PubMed Web of Science ®Google Scholar
• Smith CP, Radziszewski P, Borkowski A, et al. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64:871–875.
   PubMed Web of Science ®Google Scholar
• Hanno PM, Erickson D, Moldwin R, et al. American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193:1545–1553.
   PubMed Web of Science ®Google Scholar
• Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104:657–661.
   PubMed Web of Science ®Google Scholar
• Akiyama Y, Nomiya A, Niimi A, et al. Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response. Int J Urol. 2015;22:835–841.
   PubMed Web of Science ®Google Scholar
• Pinto R, Lopes T, Costa D, et al. Ulcerative and nonulcerative forms of bladder pain syndrome/interstitial cystitis do not differ in symptom intensity or response to onabotulinum toxin A. Urology. 2014;83:1030–1034.
   PubMed Web of Science ®Google Scholar
• Pinto R, Lopes T, Silva J, et al. Persistent therapeutic effect of repeated injections of onabotulinum toxin A in refractory bladder pain syndrome/interstitial cystitis. J Urol. 2013;189:548–553.
   PubMed Web of Science ®Google Scholar
• Lee CL, Kuo HC. Intravesical botulinum toxin A injections do not benefit patients with ulcer type interstitial cystitis. Pain Physician. 2013;16:109–116.
   PubMed Web of Science ®Google Scholar
• Petrou SP, Parker AS, Crook JE, et al. Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. Mayo Clin Proc. 2009;84:702–706.
   PubMed Web of Science ®Google Scholar
• Çetinel S, Çanıllıoğlu YE, Çikler E, et al. Leukotriene D4 receptor antagonist montelukast alleviates protamine sulphate-induced changes in rat urinary bladder. BJU Int. 2011;107(8):1320–1325.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Chess-Williams R, McDermott C. Luminal DMSO: effects on detrusor and urothelial/lamina propria function. Biomed Res Int. 2014;2014:1–8.
   Google Scholar
• Chuang YC, Tyagi P, Huang CC, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin a delivery using liposomes. J Urol. 2009;182:786–792.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Kaufmann KH, Chancellor D, et al. Bladder instillation of liposome encapsulated onabotulinumtoxin A improves overactive bladder symptoms: a prospective, multi-center, double blind, randomized trial. J Urol. 2014;192:1743–1749.
   PubMed Web of Science ®Google Scholar
• Caccin P, Rossetto O, Rigoni M, et al. VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes. FEBS Lett. 2003;542(1–3):132–136.
   PubMed Web of Science ®Google Scholar
• Mushrush DJ, Koteiche HA, Sammons MA, et al. Studies of the mechanistic details of the pH-dependent association of botulinum neurotoxin with membranes. J Biol Chem.. 2011;286(30):27011–27018.
   PubMed Web of Science ®Google Scholar
• Leaker BR, Barnes PJ, O’Connor BJ, et al. The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma. Clin Exp Allergy. 2014;44(9):1146–1153.
   PubMed Web of Science ®Google Scholar
• Kuo HC, Liu HT, Chuang YC, et al. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol. 2014;65:1117–1124.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Jain P, Shore N, et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;18(4):143ra100. doi:10.1126/scitranslmed.3003804.
   Web of Science ®Google Scholar
• Dmitrieva N, Shelton D, Rice AS, et al. The role of nerve growth factor in a model of visceral inflammation. Neuroscience. 1997;78:449–459.
   PubMed Web of Science ®Google Scholar
• Liu HT, Tyagi P, Chancellor MB, et al. Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int. 2010;106:1681–1685.
   PubMed Web of Science ®Google Scholar
• Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185:1716–1721.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Mills IW, Crook TJ, et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with non-urological associated somatic syndromes. J Urol. 2015. pii: S0022-5347(15)05216-7. [Epub ahead of print]. doi:10.1016/j.juro.2015.10.178.
   Google Scholar
• Ogawa T, Homma T, Igawa Y, et al. CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol. 2010;183:1206–1212.
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279.
   PubMed Web of Science ®Google Scholar
• Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J Urol. 2014;191:77–82.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Crossland A, Davis E, et al. Investigation of a Ca2+++ channel α2++δ ligand for the treatment of interstitial cystitis: results of a randomized, double-blind, placebo controlled phase II trial. J Urol. 2012;188:817–823.
   PubMed Web of Science ®Google Scholar
• Qiao Z, Xia C, Shen S, et al. Suppression of the PI3K pathway in vivo reduces cystitis-induced bladder hypertrophy and restores bladder capacity examined by magnetic resonance imaging. PLoS One. 2014;9(12):e114536.
   Web of Science ®Google Scholar